Health care stocks fell Tuesday afternoon with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund (XLV) easing 0.1%.
The iShares Biotechnology ETF (IBB) rose 0.1%.
In corporate news, Verastem (VSTM) shares jumped 46% after the US Food and Drug Administration accepted and granted priority review to a new drug application for its ovarian cancer drug and set an action date of June 30.
Kazia Therapeutics (KZIA) shares fell 37% after the company said it was considering options for its drug candidate paxalisib after the US Food and Drug Administration discouraged an accelerated approval process for the potential glioblastoma treatment.
Sangamo Therapeutics (SGMO) shares sank 55% after it said its partner Pfizer (PFE) decided not to proceed with further development of a new gene therapy to treat hemophilia A, a bleeding disorder.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。